CareDx Announces Publication of Pivotal AlloSure Lung Data
Transplantation Direct published AlloSure Lung data from the international, multi-center Lung Allograft Rejection Gene expression Observational (LARGO) Study. This study demonstrated that AlloSure Lung could identify patients with acute cellular rejection (ACR), a critical need for lung transplant patients whose only option to detect rejection is an invasive bronchoscopy.
In the LARGO study, AlloSure Lung results had concurrent lung histopathology that had been assessed by a blinded consensus of an expert pulmonary pathologist panel. A total of 69 unique lung transplant patients from nine centers were examined and included histopathologic diagnoses of allograft infection, normal histopathology without infection, and ACR. The authors concluded that AlloSure Lung holds promise as a non-invasive biomarker of allograft injury with ACR in lung transplant patients.
“Lung transplant patients have the lowest survival rate of any solid organ transplant, and there are few options for rejection monitoring. A non-invasive solution like AlloSure Lung becomes extremely valuable for patient care, especially in the context of the ongoing COVID-19 pandemic,” said
“AlloSure as a liquid bronchoscopy is game changing for lung transplant patients,” said
Chief Marketing Officer
Source: CareDx, Inc.